Brief: Optimi Health And Numinus Wellness To Conduct Psychedelic Lab Research And Development
02/03/2021 14:18
March 2 (Reuters) - Optimi Health Corp OPTI.CD :
* OPTIMI HEALTH AND NUMINUS WELLNESS TO CONDUCT PSYCHEDELIC
LAB
RESEARCH AND DEVELOPMENT
Source text for Eikon: ID:nGNX73N9bk
Further company coverage: OPTI.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Optimi Health
See all newsExplainer: As Trump backs psychedelics research, FDA weighs safety and access standards
Brief: Optimi Health Corp - Trial Initiation Planned For H1 2027, Dosing To Complete By End Of 2027
Brief: Optimi Health Offers 2.4 MLn Common Shares At A Public Offering Price Of US$6.25 Per Share
Brief: Optimi Health Corp Now Sees IPO Of 2.4 Million Common Shares
Trump's psychedelic drug order boosts investor interest with promise of faster reviews